The Cambridge-MIT Institute (CMI) is today launching a new initiative to unite biologists and medical researchers with physicists, engineers, computer scientists and mathematicians to work on an innovative approach to discovering the next generation of drugs.
CMI is funding a transatlantic Next-Generation Drug Discovery Community that will bring together researchers at Cambridge University and the Massachusetts Institute of Technology (MIT) with partners from the IT, pharmaceutical and biotechnology industries. They will be working on new methods of tackling the urgent and severe bottlenecks in the discovery and development of new drugs - particularly drugs for diseases with complex causes such as cancers, arthritis, multiple sclerosis, and diabetes.
Drug discovery is currently an extremely lengthy and costly process. On average, it takes new treatments $800m and twelve years to reach the market - and those are just the ones that succeed. But the sequencing of the human genome has made available a vast array of information about the many, very complex ways in which the human body works.
“Our aims are to develop safer and more effective new drugs, faster and cheaper,” says Professor Lauffenburger from MIT. “Another aim of this Community is reduce the current reliance on animal experiments to predict effects on humans.”
As part of its work, the Community is conducting two research projects. One is studying adult, blood stem cells with the aim of using them to establish new experimental systems to test the efficacy and toxicity of drugs on human physiology. The other project aims to establish new, computational methods by which drug targets can be identified from human gene- and protein-level data.
“There are major computational challenges involved,” says Dr Gos Micklem, who is part of the Cambridge team, “if we are going to make sense of all the data, and use it to start building systems-level views of life and disease processes. As we start to do this, and take into account the genetic variation between individuals, this opens up new possibilities in evaluating disease susceptibility, improved diagnosis and the ability to offer therapy tailored to each individual patient.”
The Next-Generation Drug Discovery Community is one of several new Knowledge Integration Communities (KICs) that the Cambridge-MIT Institute is setting up. These KICs aim to find new ways in which academia and industry can work together and exchange knowledge to push forward research in areas where UK industry has a demonstrable competitive position – like biotechnology and information technology . So alongside the research work, there are other strands to the Community. New educational programmes are being created. These include a new Masters degree programme at the University of Cambridge, an MPhil in Computational Biology, to teach biology to mathematicians and others, and make biologists more familiar with computer science.
Meanwhile, industry is also being informed about this work, and encouraged to join the Community.
Dr Adriano Henney, Director in Global Sciences & Information at AstraZeneca, says, “AstraZeneca, through its collaboration with MIT, already recognises the potential value of systems biology and mathematical modelling. During this collaboration, the joint project teams have prototyped the use of these approaches in drug discovery and this has helped to influence investment in the creation of a new, multidisciplinary capability in this area within the Company. We are looking forward to continuing our close collaboration with Professor Lauffenburger, and to the possibility of extending this to include Cambridge in the near future.”
Lize King | alfa
Combating sulphuric acid corrosion at wastewater plants: Graz scientists develop new solution
23.02.2018 | Technische Universität Graz
Stealth Virus for Cancer Therapy
31.01.2018 | Universität Zürich
A newly developed laser technology has enabled physicists in the Laboratory for Attosecond Physics (jointly run by LMU Munich and the Max Planck Institute of Quantum Optics) to generate attosecond bursts of high-energy photons of unprecedented intensity. This has made it possible to observe the interaction of multiple photons in a single such pulse with electrons in the inner orbital shell of an atom.
In order to observe the ultrafast electron motion in the inner shells of atoms with short light pulses, the pulses must not only be ultrashort, but very...
A group of researchers led by Andrea Cavalleri at the Max Planck Institute for Structure and Dynamics of Matter (MPSD) in Hamburg has demonstrated a new method enabling precise measurements of the interatomic forces that hold crystalline solids together. The paper Probing the Interatomic Potential of Solids by Strong-Field Nonlinear Phononics, published online in Nature, explains how a terahertz-frequency laser pulse can drive very large deformations of the crystal.
By measuring the highly unusual atomic trajectories under extreme electromagnetic transients, the MPSD group could reconstruct how rigid the atomic bonds are...
Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...
For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.
In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...
Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale
Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...
15.02.2018 | Event News
13.02.2018 | Event News
12.02.2018 | Event News
23.02.2018 | Physics and Astronomy
23.02.2018 | Health and Medicine
23.02.2018 | Physics and Astronomy